Pacific Biosciences of California, Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised
Pacific Biosciences of California, Inc. (PACB) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised of $1.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions · last filed 2026-08-06
- Pacific Biosciences of California, Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2026-06-30 was $255.00K.
- Pacific Biosciences of California, Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2026-03-31 was $1.44M, a 26.65% decline year-over-year.
- Pacific Biosciences of California, Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2025-12-31 was $0.00.
- Pacific Biosciences of California, Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2025-09-30 was $1.47M, a 80.91% increase year-over-year.
- Pacific Biosciences of California, Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2025 was $3.43M, a 55.50% decline from fiscal 2024.
- Pacific Biosciences of California, Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2024 was $7.70M, a 49.72% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2023 was $15.32M, a 36.41% increase from fiscal 2022.
- Pacific Biosciences of California, Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2022 was $11.23M.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $255.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.69M 10-Q · filed 2026-08-06 | $1.69M derived: sum of 3 quarters · filed 2026-08-06 | $3.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.44M 10-Q · filed 2026-05-08 | $1.44M derived: sum of 2 quarters · filed 2026-05-08 | $2.91M derived: sum of 3 quarters · filed 2026-05-08 | $2.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.47M derived: sum of 2 quarters · filed 2026-02-25 | $1.47M derived: sum of 3 quarters · filed 2026-08-06 | $3.43M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.47M derived: sum of 2 quarters · filed 2026-08-06 | $3.43M 10-Q · filed 2025-11-06 | $3.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.96M 10-Q · filed 2026-08-06 | $1.96M derived: sum of 3 quarters · filed 2026-08-06 | $2.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.96M 10-Q · filed 2026-05-08 | $1.96M derived: sum of 2 quarters · filed 2026-05-08 | $2.77M derived: sum of 3 quarters · filed 2026-05-08 | $2.77M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $812.00K derived: sum of 2 quarters · filed 2026-02-25 | $812.00K derived: sum of 3 quarters · filed 2026-02-25 | $7.70M 10-K · filed 2026-02-25 |
| 2024-09-30 | $812.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $812.00K derived: sum of 2 quarters · filed 2025-11-06 | $7.70M 10-Q · filed 2025-11-06 | $8.64M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $6.89M 10-Q · filed 2025-08-07 | $7.83M derived: sum of 3 quarters · filed 2026-02-25 | $12.39M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $6.89M 10-Q · filed 2025-05-12 | $7.83M derived: sum of 2 quarters · filed 2026-02-25 | $12.39M derived: sum of 3 quarters · filed 2026-02-25 | $14.97M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $936.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.50M derived: sum of 2 quarters · filed 2026-02-25 | $8.08M derived: sum of 3 quarters · filed 2026-02-25 | $15.32M 10-K · filed 2026-02-25 |
| 2023-09-30 | $4.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.15M derived: sum of 2 quarters · filed 2024-11-12 | $14.38M 10-Q · filed 2024-11-12 | $15.63M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $9.82M 10-Q · filed 2024-08-09 | $11.07M derived: sum of 3 quarters · filed 2025-03-17 | $14.61M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $7.24M 10-Q · filed 2024-05-09 | $8.48M derived: sum of 2 quarters · filed 2025-03-17 | $12.03M derived: sum of 3 quarters · filed 2025-03-17 | $12.87M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $4.79M derived: sum of 2 quarters · filed 2025-03-17 | $5.64M derived: sum of 3 quarters · filed 2025-03-17 | $11.23M 10-K · filed 2025-03-17 |
| 2022-09-30 | $3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $4.39M derived: sum of 2 quarters · filed 2023-11-03 | $9.98M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $848.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $6.44M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $5.59M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |